SmithKline Label Comprehension Studies Explore Denavir Misuse Potential
This article was originally published in The Tan Sheet
Executive Summary
The possibility that SmithKline Beecham's Denavir might be used in an OTC setting by immunocompromised consumers as well as for the treatment of genital herpes was explored in four label comprehension studies presented by the company at a joint meeting of FDA's Nonprescription and Antiviral Drugs Advisory Committees in Bethesda, Md. Dec. 1.